Journal article
Therapy for relapsed multiple myeloma
Abstract
Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our …
Authors
Aljama MA; Sidiqi MH; Dingli D
Journal
Panminerva Medica, Vol. 60, No. 4, pp. 174–184
Publisher
Edizioni Minerva Medica
Publication Date
December 2018
DOI
10.23736/s0031-0808.18.03542-5
ISSN
0031-0808
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicClinical Trials, Phase III as TopicDecision MakingGene Expression ProfilingHumansHydrazinesImmunotherapyIn Situ Hybridization, FluorescenceMultiple MyelomaNeoplasm Recurrence, LocalStem Cell TransplantationSulfonamidesSymptom AssessmentTransplantation, AutologousTriazolesWatchful Waiting